Your browser is no longer supported. Please, upgrade your browser.
CRIS Curis, Inc. monthly Stock Chart
Curis, Inc.
Index- P/E- EPS (ttm)-0.82 Insider Own9.65% Shs Outstand54.55M Perf Week11.63%
Market Cap84.07M Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float53.14M Perf Month32.11%
Income-31.00M PEG- EPS next Q-0.11 Inst Own36.80% Short Float0.81% Perf Quarter33.33%
Sales11.10M P/S7.57 EPS this Y1.50% Inst Trans2.79% Short Ratio0.77 Perf Half Y73.60%
Book/sh-0.52 P/B- EPS next Y29.00% ROA-81.30% Target Price- Perf Year-24.21%
Cash/sh0.40 P/C3.56 EPS next 5Y- ROE93.10% 52W Range0.62 - 3.59 Perf YTD-15.29%
Dividend- P/FCF- EPS past 5Y2.30% ROI82.20% 52W High-59.89% Beta2.16
Dividend %- Quick Ratio3.10 Sales past 5Y0.30% Gross Margin95.10% 52W Low132.26% ATR0.06
Employees28 Current Ratio3.10 Sales Q/Q-6.90% Oper. Margin- RSI (14)73.94 Volatility4.83% 5.79%
OptionableYes Debt/Eq- EPS Q/Q43.50% Profit Margin- Rel Volume1.05 Prev Close1.37
ShortableYes LT Debt/Eq- EarningsNov 10 AMC Payout- Avg Volume562.69K Price1.44
Recom2.00 SMA2018.47% SMA5021.40% SMA20032.81% Volume592,013 Change5.11%
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Aug-11-15Initiated FBR Capital Outperform $6
Jan-22-15Reiterated Oppenheimer Outperform $3 → $5
Jan-21-15Reiterated ROTH Capital Buy $10 → $6
May-09-14Reiterated Oppenheimer Outperform $4.50 → $3
Oct-02-13Initiated Robert W. Baird Outperform $7
Sep-30-13Initiated Chardan Capital Markets Buy $6
Nov-14-12Initiated Stifel Nicolaus Hold
Jan-31-12Reiterated Summer Street Research Buy $5 → $7
Jan-31-12Reiterated Brean Murray Buy $5 → $6
Dec-09-11Initiated Oppenheimer Outperform $6
Oct-06-11Initiated Summer Street Research Buy $5
Sep-22-11Initiated MLV Capital Buy $8.50
Mar-21-11Reiterated Brean Murray Buy $4 → $5
Feb-26-10Reiterated Roth Capital Buy $5 → $4.50
Jan-07-10Initiated Roth Capital Buy $5
Nov-24-20 09:51AM  
Nov-10-20 04:54PM  
Nov-04-20 01:29PM  
Nov-02-20 04:01PM  
Oct-21-20 08:00AM  
Oct-14-20 05:01PM  
Sep-18-20 07:05AM  
Sep-10-20 04:01PM  
Aug-04-20 04:01PM  
Jul-28-20 08:00AM  
Jul-07-20 08:00AM  
Jun-21-20 10:09PM  
Jun-11-20 09:25AM  
Jun-10-20 08:00AM  
Jun-04-20 07:24PM  
Jun-03-20 09:33AM  
May-12-20 04:01PM  
May-05-20 08:00AM  
Apr-07-20 08:00AM  
Apr-03-20 04:01PM  
Mar-19-20 04:01PM  
Mar-12-20 08:00AM  
Feb-27-20 08:00AM  
Feb-06-20 08:30AM  
Jan-13-20 08:00AM  
Jan-08-20 04:31PM  
Jan-07-20 08:05AM  
Dec-23-19 06:24PM  
Dec-22-19 08:33AM  
Dec-06-19 07:26AM  
Nov-20-19 10:07PM  
Nov-06-19 09:05AM  
Nov-05-19 07:00AM  
Oct-31-19 04:16PM  
Oct-29-19 08:00AM  
Oct-04-19 04:05PM  
Sep-26-19 08:00AM  
Sep-23-19 12:07PM  
Sep-12-19 08:00AM  
Aug-06-19 04:01PM  
Jul-30-19 08:00AM  
Jul-25-19 03:49PM  
Jul-05-19 04:01PM  
Jun-12-19 07:00AM  
May-21-19 11:20AM  
May-14-19 04:29PM  
May-07-19 08:00AM  
May-06-19 08:00AM  
Apr-26-19 03:13PM  
Apr-10-19 08:00AM  
Apr-05-19 04:30PM  
Mar-27-19 10:16PM  
Mar-26-19 04:17PM  
Mar-25-19 12:05PM  
Mar-04-19 08:00AM  
Feb-04-19 07:00AM  
Jan-29-19 09:30AM  
Jan-24-19 07:00AM  
Jan-10-19 05:53PM  
Jan-08-19 12:58PM  
Jan-04-19 04:00PM  
Nov-30-18 07:45AM  
Nov-20-18 10:45AM  
Nov-07-18 04:05PM  
Nov-05-18 09:09AM  
Nov-01-18 10:41AM  
Oct-23-18 04:29PM  
Oct-19-18 10:39AM  
Oct-10-18 06:44PM  
Oct-05-18 07:00AM  
Sep-27-18 11:44AM  
Sep-26-18 04:05PM  
Sep-24-18 04:22PM  
Aug-29-18 07:45AM  
Aug-28-18 04:14PM  
Aug-05-18 11:18PM  
Aug-02-18 11:50AM  
Jul-27-18 08:30AM  
Jul-26-18 07:55AM  
Jul-09-18 10:33AM  
Jun-11-18 09:32AM  
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dentzer James EPresident & CEOJan 24Sale1.643,0945,07642,158Jan 24 06:10 PM
Dentzer James EPresident & CEOJan 23Sale1.693,6586,18245,252Jan 24 06:10 PM